Century Therapeutics (IPSC) CEO discloses tax withholding of 463 shares
Rhea-AI Filing Summary
Century Therapeutics, Inc.'s president and CEO, who is also a director, reported an automatic share withholding related to equity compensation. On 12/10/2025, 463 shares of common stock were withheld at $0.526 per share to cover tax obligations triggered by the vesting of restricted stock units. After this transaction, the executive directly owns 3,270,990 shares of Century Therapeutics common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise Price or Tax Liability | Common Stock | 463 | $0.526 | $243.54 |
Footnotes (1)
- F1. Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Century Therapeutics (IPSC) report in this filing?
The president and CEO of Century Therapeutics, Inc. (IPSC) reported an automatic withholding of common shares to satisfy tax obligations arising from the vesting of restricted stock units.
Does this Century Therapeutics (IPSC) filing reflect an open-market sale by the CEO?
No. The explanation states that the reported shares represent stock withheld by the issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units, not an open-market sale.
When did the reported Century Therapeutics (IPSC) insider transaction occur?
The earliest transaction date reported in the filing is 12/10/2025, when the tax-related share withholding tied to vested restricted stock units took place.
What roles does the reporting person hold at Century Therapeutics (IPSC)?
The reporting person is identified as both a director and an officer, serving as the President and CEO of Century Therapeutics, Inc.